MX2022012056A - Pirrolopirimidinaminas como inhibidores del sistema del complemento. - Google Patents
Pirrolopirimidinaminas como inhibidores del sistema del complemento.Info
- Publication number
- MX2022012056A MX2022012056A MX2022012056A MX2022012056A MX2022012056A MX 2022012056 A MX2022012056 A MX 2022012056A MX 2022012056 A MX2022012056 A MX 2022012056A MX 2022012056 A MX2022012056 A MX 2022012056A MX 2022012056 A MX2022012056 A MX 2022012056A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolopyrimidine
- amines
- complement inhibitors
- compounds
- complement system
- Prior art date
Links
- -1 Pyrrolopyrimidine amines Chemical class 0.000 title 1
- 239000004074 complement inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004154 complement system Effects 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compuestos de Fórmula (I) y sus sales farmacéuticamente aceptables, que son inhibidores del sistema del complemento. También, composiciones farmacéuticas que comprenden un compuesto con dichas características y métodos para usar los compuestos y composiciones en el tratamiento o la prevención de una enfermedad o condición caracterizada por una actividad aberrante del sistema del complemento. (ver Fórmula) (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004799P | 2020-04-03 | 2020-04-03 | |
PCT/US2021/025547 WO2021202977A1 (en) | 2020-04-03 | 2021-04-02 | Pyrrolopyrimidine amines as complement inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022012056A true MX2022012056A (es) | 2022-10-13 |
Family
ID=77929437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022012056A MX2022012056A (es) | 2020-04-03 | 2021-04-02 | Pirrolopirimidinaminas como inhibidores del sistema del complemento. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20230159536A1 (es) |
EP (1) | EP4125914A4 (es) |
JP (1) | JP2023519824A (es) |
KR (1) | KR20220163955A (es) |
CN (1) | CN115427044A (es) |
AR (1) | AR121715A1 (es) |
AU (1) | AU2021246098A1 (es) |
BR (1) | BR112022018067A2 (es) |
CA (1) | CA3176808A1 (es) |
CL (1) | CL2022002649A1 (es) |
CO (1) | CO2022015630A2 (es) |
CR (1) | CR20220553A (es) |
CU (1) | CU20220060A7 (es) |
DO (1) | DOP2022000211A (es) |
EC (1) | ECSP22085221A (es) |
IL (1) | IL296978A (es) |
JO (1) | JOP20220227A1 (es) |
MX (1) | MX2022012056A (es) |
PE (1) | PE20230601A1 (es) |
TW (1) | TW202204358A (es) |
UY (1) | UY39150A (es) |
WO (1) | WO2021202977A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3234428A1 (en) * | 2021-10-18 | 2023-04-27 | Nader Najafian | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
WO2024047078A1 (en) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Dosage regimen of vicasinabin |
US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
US9085555B2 (en) * | 2011-01-04 | 2015-07-21 | Novartis Ag | Complement pathway modulators and uses thereof |
-
2021
- 2021-03-31 AR ARP210100817A patent/AR121715A1/es unknown
- 2021-04-01 TW TW110112139A patent/TW202204358A/zh unknown
- 2021-04-02 WO PCT/US2021/025547 patent/WO2021202977A1/en active Application Filing
- 2021-04-02 JP JP2022556491A patent/JP2023519824A/ja active Pending
- 2021-04-02 CA CA3176808A patent/CA3176808A1/en active Pending
- 2021-04-02 IL IL296978A patent/IL296978A/en unknown
- 2021-04-02 CU CU2022000060A patent/CU20220060A7/es unknown
- 2021-04-02 KR KR1020227033595A patent/KR20220163955A/ko active Search and Examination
- 2021-04-02 MX MX2022012056A patent/MX2022012056A/es unknown
- 2021-04-02 US US17/915,179 patent/US20230159536A1/en active Pending
- 2021-04-02 EP EP21781014.2A patent/EP4125914A4/en active Pending
- 2021-04-02 CR CR20220553A patent/CR20220553A/es unknown
- 2021-04-02 AU AU2021246098A patent/AU2021246098A1/en active Pending
- 2021-04-02 JO JOP/2022/0227A patent/JOP20220227A1/ar unknown
- 2021-04-02 CN CN202180025930.0A patent/CN115427044A/zh active Pending
- 2021-04-02 BR BR112022018067A patent/BR112022018067A2/pt unknown
- 2021-04-02 PE PE2022002121A patent/PE20230601A1/es unknown
- 2021-04-05 UY UY0001039150A patent/UY39150A/es unknown
-
2022
- 2022-09-28 DO DO2022000211A patent/DOP2022000211A/es unknown
- 2022-09-28 CL CL2022002649A patent/CL2022002649A1/es unknown
- 2022-10-31 CO CONC2022/0015630A patent/CO2022015630A2/es unknown
- 2022-11-02 EC ECSENADI202285221A patent/ECSP22085221A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202204358A (zh) | 2022-02-01 |
PE20230601A1 (es) | 2023-04-10 |
AU2021246098A1 (en) | 2022-10-20 |
CO2022015630A2 (es) | 2022-11-29 |
JOP20220227A1 (ar) | 2023-01-30 |
CL2022002649A1 (es) | 2023-05-26 |
BR112022018067A2 (pt) | 2022-10-25 |
UY39150A (es) | 2021-10-29 |
EP4125914A1 (en) | 2023-02-08 |
EP4125914A4 (en) | 2024-07-03 |
CA3176808A1 (en) | 2021-10-07 |
WO2021202977A1 (en) | 2021-10-07 |
KR20220163955A (ko) | 2022-12-12 |
JP2023519824A (ja) | 2023-05-15 |
CR20220553A (es) | 2023-02-03 |
AR121715A1 (es) | 2022-06-29 |
CN115427044A (zh) | 2022-12-02 |
ECSP22085221A (es) | 2022-12-30 |
DOP2022000211A (es) | 2022-11-15 |
CU20220060A7 (es) | 2023-05-11 |
US20230159536A1 (en) | 2023-05-25 |
IL296978A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022012056A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento. | |
MX2018008869A (es) | Compuestos de benzopirazol y análogos de estos. | |
MX2023007192A (es) | Inhibidores de prmt5. | |
PH12021551529A1 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
JOP20220075A1 (ar) | مثبطات عامل d المكمل عن طريق الفم | |
MX2022014817A (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados. | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
MX2022004264A (es) | Inhibidores del factor d del complemento para administracion oral. | |
MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
MX2021014372A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
MX2021011144A (es) | Derivados de las benzodiazepinas como inhibidores del vsr. | |
MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
MX2022008487A (es) | Degradadores de smarca2-vhl. | |
MX2023011297A (es) | Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6). | |
MX2022009898A (es) | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. | |
WO2021133894A8 (en) | Btk inhibitors | |
MY160963A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
WO2020096916A3 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection | |
MX2023012120A (es) | Inhibidores heteroaromaticos biciclicos de la klk5. |